Anbio Biotechnology (NASDAQ:NNNN) Short Interest Update

Anbio Biotechnology (NASDAQ:NNNN) was the recipient of a significant decrease in short interest during the month of July. As of July 15th, there was short interest totaling 31,583 shares, a decrease of 64.6% from the June 30th total of 89,295 shares. Based on an average daily trading volume, of 42,616 shares, the short-interest ratio is currently 0.7 days. Approximately 0.0% of the company’s stock are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded Anbio Biotechnology from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, May 14th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, Anbio Biotechnology has an average rating of “Hold”.

Anbio Biotechnology Trading Down 2.1%

NASDAQ:NNNN traded down $0.20 during midday trading on Monday, reaching $9.70. The stock had a trading volume of 4,199 shares, compared to its average volume of 43,938. Anbio Biotechnology has a 1-year low of $8.30 and a 1-year high of $54.95. The business has a fifty day moving average price of $18.43.

About Anbio Biotechnology

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.